Polycystic ovary syndrome (PCOS) is the most common cause of ovulatory disorders and female infertility. Signs and symptoms of PCOS may include anovulation or menstrual irregularities, ovarian cysts on ultrasound, hyperandrogenism including hirsutism, acne, and alopecia, insulin resistance, and obesity. Insulin resistance and secondary hyperinsulinemia appear to play a causative role in the development of PCOS. In addition, PCOS patients suffer from elevated oxidative stress and systemic inflammation. Myo‑inositol has been suggested as first-line therapy in the management of PCOS and has been shown to be effective in mitigating the symptoms of this syndrome and its associated comorbidities.
As an essential component of phospholipids, inositol can assist in regulating cellular response for healthy body functioning. NFH Inositol SAP helps to improve ovarian function in women with oligomenorrhea and polycystic ovaries. NFH Inositol SAP assists in the management of polycystic ovarian syndrome (PCOS) by helping to restore normal ovarian function; by reducing oxidative stresses to restore ovulation and oocyte quality. This product works to normalize menstrual cycle irregularities, minimize serum testosterone in women with PCOS, and manage PCOS’s hormonal and metabolic conditions by promoting healthy glucose metabolism.
